Anacor Pharmaceuticals, Inc. Reports Third Quarter 2013 Financial Results

Published: Nov 08, 2013

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Anacor Pharmaceuticals (NASDAQ:ANAC) today announced its financial results for the third quarter ended September 30, 2013.

“We had an eventful third quarter – we filed an NDA for tavaborole, our most advanced product candidate, and received acceptance for filing from the FDA. In addition, in October we negotiated a $142.5 million settlement of our disputes with Valeant Pharmaceuticals, which will provide us with significant flexibility as we pursue our business plan,” said David Perry, Chief Executive Officer of Anacor Pharmaceuticals.

Help employers find you! Check out all the jobs and post your resume.

Back to news